- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02769039
Predictors of Motor Progression in Parkinson's Disease
June 4, 2019 updated by: University of Minnesota
Predictors of Progression to Freezing of Gait in Parkinson's Disease
Treatment resistant motor features, such as postural instability and freezing of gait are common in people with Parkinson's disease and major contributors to morbidity and mortality.
This project will use sleep studies, quantitative motor assessments and magnetic resonance imaging to examine the relationship between abnormally increased muscle activity during rapid eye movement sleep and the development and progression of treatment-resistant postural instability and gait disturbances.
Specifically, the investigators will test the hypothesis that anticipatory postural adjustments (weight and pressure shifts) during gait initiation are significantly reduced in people with Parkinson's disease who have abnormally elevated muscle activity during rapid eye movement (REM) sleep compared to individuals will Parkinson's disease whose REM sleep muscle activity is normal.
In addition, the investigators will test the hypothesis that the level of RSWA at baseline is predictive of measures of motor decline (postural stability and gait) and alterations in the structure and function of locomotor brainstem networks.
Since sleep disorders can emerge years before a diagnosis of Parkinson's disease, establishment of a link between sleep and treatment-resistant posture and gait disorders will help identify individuals at risk of developing these disabling motor features of disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
72
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Parkinson's Disease
Description
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's Disease (PD).
- Age 21-75 years
- Able to ambulate independently without the use of an assistive device (e.g. cane)
Exclusion Criteria:
- History of Dementia
- History of musculoskeletal disorders that adversely affects walking and/or balance
- Other significant neurological disorders
- Implanted deep brain stimulator(s) (DBS) or other neurosurgeries to treat PD
- MRI exclusion for 7 tesla scans: presence of any metallic clips or implantable medical devices
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Parkinson's Disease participants
People with early Parkinson's disease with mild-to-moderate severity of disease.
|
Participants will be asked to visit the University for 3 baseline visits which include a screening visit & sleep study, movement tests and magnetic resonance imaging (MRI) scans.
Three years later the participant will be asked to repeat the same visits.
|
Control participants
Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
|
Participants will be asked to visit the University for 3 baseline visits which include a screening visit & sleep study, movement tests and magnetic resonance imaging (MRI) scans.
Three years later the participant will be asked to repeat the same visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Magnitude of the center of pressure shift during gait initiation.
Time Frame: Measured at baseline (time 0).
|
The magnitude of the center of pressure shift during gait initiation is calculated as the displacement of the center of pressure signal from quiet standing (baseline) to the peak lateral and posterior excursion during the anticipatory postural adjustment phase of gait initiation.
|
Measured at baseline (time 0).
|
Correlation between measures of REM sleep without atonia (RSWA) at baseline and change in the magnitude of the center of pressure shift during gait initiation over the course of 3 years.
Time Frame: Change in magnitude over the course of 3 years
|
A linear correlation analysis will be conducted between measures of RSWA at baseline versus the change in shift of the center of pressure during gait initiation between baseline and year 3.
|
Change in magnitude over the course of 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
May 31, 2019
Study Completion (Actual)
May 31, 2019
Study Registration Dates
First Submitted
April 27, 2016
First Submitted That Met QC Criteria
May 9, 2016
First Posted (Estimate)
May 11, 2016
Study Record Updates
Last Update Posted (Actual)
June 5, 2019
Last Update Submitted That Met QC Criteria
June 4, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1508M77201
- 1R01NS088679-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on No intervention. Observational studies of sleep, movement and brain imaging
-
Zhujiang HospitalNational Natural Science Foundation of ChinaRecruitingColorectal Cancer | Inflammatory Bowel Disease | Type2 Diabetes Mellitus | Atherosclerotic Cardiovascular DiseaseChina
-
Zhujiang HospitalNational Natural Science Foundation of ChinaRecruitingMultiple Myeloma | Monoclonal Gammopathies | M-proteinChina
-
Western Sydney Local Health DistrictUniversity of Western SydneyRecruitingHepatitis | Lung Cancer, Non-small Cell | Lung Cancer Stage IVAustralia
-
BG Trauma Center TuebingenCompletedHand InfectionsGermany
-
Xin HuangRecruitingCardiovascular Diseases | Vascular Diseases | Stroke | Central Nervous System Diseases | Nervous System Diseases | Brain Ischemia | Cerebral Infarction | Brain InfarctionChina
-
Ain Shams UniversityCompletedPneumonia, Viral | Critical IllnessEgypt
-
Tehran University of Medical SciencesUnknownMetabolic Syndrome XIran, Islamic Republic of
-
Italian Sarcoma GroupPharmaMarRecruitingSoft Tissue Sarcoma | Leiomyosarcoma of OvaryItaly
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Tumors Metastatic to Brain | Adult Anaplastic OligoastrocytomaUnited States
-
Seoul National University HospitalDong-A ST Co., Ltd.Not yet recruiting